Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Nattokinase

Nattokinase (Bacillus subtilis fibrinolytic enzyme) · also known as Nattokinase, NK, Nattokinase (FU)

Nattokinase has direct fibrinolytic activity in vitro. After a single 2000 FU oral dose, small human trials show brief changes in fibrinolysis markers such as D-dimer. Long-term clinical benefit has not been confirmed.

Typical dose: 2000–4000 FU/day, taken in the evening with water
Absorption and forms: Potency is labeled in fibrinolytic units (FU). As a protease of about 28 kDa, whether it enters the blood in large amounts in active form after oral intake is still disputed. Small human studies observed brief changes in fibrinolysis markers such as D-dimer and FDP after a single 2000 FU dose. It is usually taken in the evening.

Clinical uses and human evidence

High blood pressure

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Li 2023 · Rev Cardiovasc Med · Meta-analysis · n=546 — Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Hodis 2021 · Clin Hemorheol Microcirc · RCT · n=265 — Nattokinase atherothrombotic prevention study: A randomized controlled trial

Heart attack, stroke and other cardiovascular events

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Zhang 2026 · J Stroke Cerebrovasc Dis · RCT · n=120 — Nattokinase supplementation for cognitive enhancement in asymptomatic intracranial/carotid stenosis: A randomized controlled trial

High LDL cholesterol

No benefitGrade B · Moderate evidence
Studies (2)
  1. Li 2023 · Rev Cardiovasc Med · Meta-analysis · n=546 — Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Yang 2009 · Asia Pac J Clin Nutr · RCT · n=47 — Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia

Mechanisms of action

Fibrin-specific breakdown and activation of the endogenous fibrinolytic system

★★★☆☆Mechanism evidence: grade APrimary target

Nattokinase has direct fibrinolytic activity in vitro. A single 2000 FU dose can briefly raise fibrin degradation markers in humans, but it is unclear whether the active enzyme reaches the blood reliably. Direct cleavage of fibrin or inactivation of PAI-1 has also not been confirmed in humans.

References (2)
  1. Kurosawa et al. 2015 · Randomized double-blind crossover trial in 12 people: after a single 2000 FU dose, D-dimer and fibrin degradation products rose briefly
  2. Hodis et al. 2021 · RCT in 265 people: long-term daily 2000 FU showed no significant benefit on atherosclerosis progression or lab markers

Safety and drug interactions

Contraindicated in active internal bleeding. People taking anticoagulants (such as warfarin or rivaroxaban) or antiplatelet drugs (such as aspirin) should not take it on their own, and a physician must assess bleeding risk before the two are combined. It must be stopped before major surgery, but there is no validated standard for how far in advance, so the surgical team should decide based on bleeding risk and all medications taken. People with a severe soy allergy should confirm the fermentation source of the enzyme.

Additive bleeding risk

Has fibrinolytic activity. Each of these has a mild antiplatelet or fibrinolytic effect. Alone, the effect is usually small, but when several are combined, the tendency to bleed becomes more noticeable. Stop them 1–2 weeks before surgery or a tooth extraction, and watch for gum bleeding or more bruising.

Low blood pressure risk

Can mildly lower blood pressure in small trials. Each of these lowers blood pressure to some degree. People who combine several, whose blood pressure is already low, or who take blood pressure medication may feel dizzy or weak when standing up.

Open in the interactive app ›